Objective: To improve the synthesis process of rivaroxaban while avoiding the patent protection of rivaroxaban. Methods: (S)-(+)-N-(2,3-Epoxypropyl)phthalimide and 4-(4-aMinophenyl)Morpholin-3-one were used as raw materials for the final synthesis of rivaroxaban through condensation, cyclization, hydrolysis and acylation reactions. Results: In the study, the methanesulfonic acid was used instead of hydrochloric acid to synthesize the rivaroxaban intermediate 4-[4-[(5S)-5(aminomethyl)-2-carbonyl-3-azolidinyl]phenyl]-3-morpholinone methanesulfonate, avoiding patent protection. Also, the steps of hydrolysis, acylation and the final refined product in the route were optimized to achieve a product yield of 96.86 %. Conclusion: The optimized process not only avoids the problems of patent protection in the original route, but also improves the problems in the original route, thus greatly improving the safety and feasibility of the operation, and better meeting the requirements of industrial production.
LIU Yujian
,
FU Xinyue
,
ZHOU Wei
,
BAI Wanfu
. Improvement of Synthesis Process of Rivaroxaban[J]. Journal of Baotou Medical College, 2022
, 38(12)
: 76
-80
.
DOI: 10.16833/j.cnki.jbmc.2022.12.015
[1] 陈浩, 王永庆, 孟玲, 等. 凝血因子Xa抑制剂研究进展[J]. 药学与临床研究, 2013, 21(6):655-659.
[2] Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: a new oral factor Xa inhibitor[J]. Arterioscler Thromb Vasc Biol, 2010, 30(3):376-381.
[3] Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity 1[J]. J Clin Pharmacol, 2007, 47(11):1398-1407.
[4] Buller HR, Prins MH, Lensin AW. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J]. N Engl J Med, 2012, 366(14):1287.
[5] Mega JL, Braunwald E, Wiviott S D, et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 366(1):9-19.
[6] Mega JL, Braunwald E, Wiviott S D, et al. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome[J].Am J Cardiol, 2013, 112(4):472-478.
[7] Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism.[J]. N Engl J Med, 2010, 363(26):2499.
[8] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med,2011, 365(10):883-891.
[9] 李超, 郭锦材, 张拥军, 等. 利伐沙班合成路线图解[J]. 中国医药工业杂志, 2012, 43(12):1046-1048.
[10] 李杰, 潘辛梅, 赖永莉. 利伐沙班的合成研究进展[J]. 山东化工, 2018, 47(6):48-53.
[11] M·贝尔维, C·托马斯, J·雷泽,等. 制备方法[P]. 德国,CN1906191,2007-01-31.
